Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | HPGD | P15428 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | JAK2 | O60674 | 2/20 | 0.50 |
| ▸ | JAK3 | P52333 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.50 |
| ▸ | RELA | Q04206 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL320357 | 0.89 | TSHR (0.53) | TSHRALDH1A1ADORA3SMN1; SMN2MAPT | |
| SCHEMBL2673120 | 0.87 | ALDH1A1 (0.50) | TSHRALDH1A1SMN1; SMN2MAPTHPGD | |
| SCHEMBL8665022 | 0.84 | PRKCZ (0.52) | TSHRALDH1A1SMN1; SMN2MAPTHPGD | |
| SCHEMBL6976375 | 0.84 | TSHR (0.46) | TSHRALDH1A1SMN1; SMN2MAPTRAB9A | |
| SCHEMBL6164247 | 0.84 | HTT (0.50) | TSHRALDH1A1SMN1; SMN2MAPTRAB9A | |
| SCHEMBL4491165 | 0.84 | ALDH1A1 (0.55) | TSHRALDH1A1SMN1; SMN2MAPTHPGD | |
| SCHEMBL30449056 | 0.84 | ALDH1A1 (0.54) | TSHRALDH1A1SMN1; SMN2MAPTHPGD | |
| SCHEMBL4527107 | 0.83 | ALDH1A1 (0.64) | TSHRALDH1A1SMN1; SMN2MAPTHSD17B10 | |
| SCHEMBL6164316 | 0.83 | RAB9A (0.56) | TSHRALDH1A1SMN1; SMN2MAPTHPGD | |
| SCHEMBL30407 | 0.83 | JAK2 (0.56) | TSHRALDH1A1SMN1; SMN2MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116348568-A | perylene-BODIPY ternary compounds for horticultural use | 日东电工株式会社 | 2023-06-27 | — | — | CN | disclosed |
| US-11566025-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-01-31 | — | — | US | disclosed |
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S R L (IT) | 2021-10-21 | — | — | US | disclosed |
| CN-105283451-B | Novel inhibitors of viral replication | 鲁汶天主教大学 | 2021-01-26 | — | — | CN | disclosed |
| EP-2978753-B1 | NOVEL VIRAL REPLICATION INHIBITORS | UNIV LEUVEN KATH (BE) | 2020-08-12 | — | — | EP | disclosed |
| US-20200223845-A1 | NOVEL VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2020-07-16 | — | — | US | disclosed |
| US-10633378-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2020-04-28 | — | — | US | disclosed |
| US-20160297810-A1 | NOVEL VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2016-10-13 | — | — | US | disclosed |
| EP-2978753-A1 | NOVEL VIRAL REPLICATION INHIBITORS | Katholieke Universiteit Leuven (BE) | 2016-02-03 | — | — | EP | disclosed |
| US-7112675-B2 | Pyrrolotriazine inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-26 | — | — | US | disclosed |
| US-20060128709-A1 | Pyrrolotriazine inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY | 2006-06-15 | — | — | US | disclosed |
| EP-1669071-A1 | Pyrrolotriazine inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1183033-B1 | PYRROLOTRIAZINE INHIBITORS OF KINASES | BRISTOL MYERS SQUIBB CO (US) | 2006-03-01 | — | — | EP | disclosed |
| US-20060004007-A1 | Pyrrolotriazine inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-05 | — | — | US | disclosed |
| US-6982265-B1 | Pyrrolotriazine inhibitors of kinases | BRISTOL MYERS SQUIBB COMPANY (US) | 2006-01-03 | — | — | US | disclosed |
| WO-2005040127-A1 | NOVEL COMPOUNDS AS AGONIST FOR PPAR GAMMA AND PPAR ALPHA, METHOD FOR PREPARATION OF THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG LIFE SCIENCES LTD. (KR) | 2005-05-06 | — | — | WO | disclosed |
| EP-1183033-A4 | PYRROLOTRIAZINE INHIBITORS OF KINASES | BRISTOL MYERS SQUIBB CO (US) | 2002-07-17 | — | — | EP | disclosed |
| EP-1183033-A1 | PYRROLOTRIAZINE INHIBITORS OF KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000071129-A1 | PYRROLOTRIAZINE INHIBITORS OF KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566025-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | TSHR 4827/4885ALDH1A1 4277/4885ADORA3 2999/4885 |
| US-20160297810-A1 | NOVEL VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, IRF3 | TSHR 4803/4885ALDH1A1 4494/4885ADORA3 3304/4885 |
| US-20060128709-A1 | Pyrrolotriazine inhibitors of kinases | FGFR1, FGFR2, ERBB2 | TSHR 1494/4885ALDH1A1 1255/4885ADORA3 4252/4885 |
| US-20060004007-A1 | Pyrrolotriazine inhibitors of kinases | FGFR1, FGFR2, ERBB2 | TSHR 1494/4885ALDH1A1 1255/4885ADORA3 4252/4885 |
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | TSHR 1446/4885ALDH1A1 2328/4885ADORA3 2866/4885 |
| US-10633378-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | TSHR 4827/4885ALDH1A1 4277/4885ADORA3 2999/4885 |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | TSHR 1446/4885ALDH1A1 2328/4885ADORA3 2866/4885 |
| US-20200223845-A1 | NOVEL VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, IRF3 | TSHR 4803/4885ALDH1A1 4494/4885ADORA3 3304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.